Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - cytarabin - injektions-/infusionsvæske, opløsning - 100 mg/ml

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

stada nordic aps - cefalexinmonohydrat - tabletter - 500 mg

Danimarca - danese - SEGES Landbrug & Fødevarer

bayer a/s - imidacloprid - granulat - 5 g/kg imidacloprid

Unione Europea - danese - EMA (European Medicines Agency)

steba biotech s.a - padeliporfin di-kalium - prostatiske neoplasmer - antineoplastiske midler - tookad er angivet som monoterapi til voksne patienter med tidligere ubehandlet, ensidige, lav risiko, adenocarcinom i prostata med en forventet levetid ≥ 10 år og kliniske fase t1c eller t2a;gleason score ≤ 6, der er baseret på high-resolution biopsi strategier, psa ≤ 10 ng/ml;3 positive kræft-kerner med en maksimal kræft længde på 5 mm i en kerne eller 1-2 positiv kræft kerner med ≥ 50 % kræft engagement i en kerne eller en psa massefylde ≥ 0. 15 ng/ml/cm3.

Unione Europea - danese - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter, der har en lav eller meget lav risiko for tilbagefald, bør ikke modtage adjuverende behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. undtagen i nyligt diagnosticeret kronisk cml-fase, der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.

Unione Europea - danese - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - antitrombotiske midler - prevention of venous thromboembolic events.

Unione Europea - danese - EMA (European Medicines Agency)

zoetis belgium sa - maropitant citrat - alimentary tract and metabolism - dogs; cats - tabletter hunde: til forebyggelse af kvalme induceret ved kemoterapi. til forebyggelse af opkast induceret af motion sygdom. til forebyggelse og behandling af opkastning i forbindelse med cerenia injektionsvæske, opløsning og i kombination med andre understøttende foranstaltninger. løsning til injectiondogs:til behandling og forebyggelse af kvalme, der er fremkaldt af kemoterapi. til forebyggelse af opkastning bortset fra det, der induceres af motionssygdom. til behandling af opkastning, i kombination med andre understøttende foranstaltninger. til forebyggelse af perioperative kvalme og opkastning og forbedring i nyttiggørelse af generel anæstesi efter brug af μ-opioid receptor agonist morfin. katte: til forebyggelse af opkastning og reduktion af kvalme, bortset fra det, der fremkaldes af bevægelsessyge. til behandling af opkastning, i kombination med andre understøttende foranstaltninger.

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

serb s.a. - kaliumiodid - tabletter - 65 mg

Unione Europea - danese - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatiske neoplasmer - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Danimarca - danese - SEGES Landbrug & Fødevarer

syngenta nordics a/s - difenoconazol, fludioxonil, sedaxan - flydende bejdse - 25 g/l difenoconazol; 25 g/l fludioxonil; 50 g/l sedaxane